“Whatever happened to the polypill?” my colleagues ask me when told about the status of fixed-dose combination therapy for cardiovascular disease prevention. While the concept has always seemed straightforward, the implementation of this apparently simple concept has proved more challenging than anticipated. More than a decade after the concept was introduced, the state of the ...
Whatever happened to the polypill?
By Mark D. Huffman
17 Aug 2015